Post-Interleukin 1
| Zeile 3: | Zeile 3: | ||
{{tp|p=32228825|t=2020. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1 |pdf=|usr=}} | {{tp|p=32228825|t=2020. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1 |pdf=|usr=}} | ||
{{tp|p=32373790|t=2020. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome |pdf=|usr=}} | {{tp|p=32373790|t=2020. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome |pdf=|usr=}} | ||
| − | {{tp|p=32482538|t=ä. Propuesta de uso de anakinra en el | + | {{tp|p=32482538|t=ä. Propuesta de uso de anakinra en el distres respiratorio agudo secundario a COVID-19 |pdf=|usr=}} |
{{tp|p=32456767|t=2020. Anakinra in COVID-19 therapy: what have we learned from adult-onset Still's disease?|pdf=|usr=007}} | {{tp|p=32456767|t=2020. Anakinra in COVID-19 therapy: what have we learned from adult-onset Still's disease?|pdf=|usr=007}} | ||
{{tp|p=32438450|t=2020. Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.|pdf=|usr=007}} | {{tp|p=32438450|t=2020. Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.|pdf=|usr=007}} | ||
| + | |||
| + | {{tp|p=32422376|t=2020. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report.|pdf=|usr=008}} | ||
| + | {{tp|p=32437934|t=2020. Use of anakinra in severe COVID-19: a case report.|pdf=|usr=008}} | ||
{{tp|p=32487869|t=2020. COVID-19 and myocardial injury: is there a role for interleukin-1 inhibition?|pdf=|usr=007}} | {{tp|p=32487869|t=2020. COVID-19 and myocardial injury: is there a role for interleukin-1 inhibition?|pdf=|usr=007}} | ||
Version vom 27. Juni 2020, 13:11 Uhr
32313848 ä. Precision medicine in COVID-19: IL-1 beta a potential target
32376597 2020. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series
32228825 2020. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1
32373790 2020. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome
32482538 ä. Propuesta de uso de anakinra en el distres respiratorio agudo secundario a COVID-19
32456767 2020. Anakinra in COVID-19 therapy: what have we learned from adult-onset Still's disease?
32438450 2020. Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.
32422376 2020. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report.
32437934 2020. Use of anakinra in severe COVID-19: a case report.
32487869 2020. COVID-19 and myocardial injury: is there a role for interleukin-1 inhibition?
